ZBIO Earnings Date: Nov 18, 2026 (Estimated) — Zenas BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ZBIO's next earnings date?
Zenas BioPharma, Inc. (ZBIO) is expected to report earnings on Wednesday, November 18, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.24 on revenue of $1.0M.
How did ZBIO do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Zenas BioPharma, Inc. posted EPS of -$1.77 versus the -$0.78 estimate, a miss of 126.9%. Revenue was $1.0M against a $27.0M estimate. The stock's 1-day post-earnings move was -6.7%.
How much does ZBIO stock move after earnings?
ZBIO beat EPS estimates in 1 of its last 5 reported quarters. Over the last 6 reports the stock moved an average of 5.4% (up or down) in the day after earnings.
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.78 | -1.77 | -126.92% | $1.0M | ❌ Miss | -6.68% | -0.13% | -0.54% |
| 2026-08-12 | -1.12 | -1.77 | -58.04% | $1.0M | ❌ Miss | -9.99% | -1.63% | -4.13% | |
| 2026-05-13 | Q1 2026 | -1.54 | -1.46 | +5.19% | $0 | ✅ Beat | +4.02% | -6.89% | -7.31% |
| 2026-03-16 | Q4 2025 | — | -4.54 | — | $0 | — | -3.37% | -7.24% | -11.23% |
| 2025-11-12 | Q3 2025 | -0.98 | -1.22 | -24.49% | $0 | ❌ Miss | +1.70% | +2.87% | +14.23% |
| 2025-08-12 | Q2 2025 | -1.04 | -1.25 | -20.19% | $0 | ❌ Miss | +6.68% | +15.93% | +32.77% |
| 2022-12-31 | — | -0.50 | — | — | — | — | — | — |
Showing last 7 quarters.